Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $7.51 HKD
Change Today +0.09 / 1.21%
Volume 1.1M
2348 On Other Exchanges
Symbol
Exchange
OTC US
Hong Kong
As of 4:01 AM 07/31/15 All times are local (Market data is delayed by at least 15 minutes).

dawnrays pharmaceutical hold (2348) Snapshot

Open
$7.42
Previous Close
$7.42
Day High
$7.55
Day Low
$7.22
52 Week High
10/22/14 - $8.13
52 Week Low
02/11/15 - $3.91
Market Cap
6.0B
Average Volume 10 Days
1.1M
EPS TTM
$0.25
Shares Outstanding
804.3M
EX-Date
05/27/15
P/E TM
23.6x
Dividend
$0.11
Dividend Yield
1.46%
Current Stock Chart for DAWNRAYS PHARMACEUTICAL HOLD (2348)

Related News

No related news articles were found.

dawnrays pharmaceutical hold (2348) Related Businessweek News

No Related Businessweek News Found

dawnrays pharmaceutical hold (2348) Details

Dawnrays Pharmaceutical (Holdings) Limited, an investment holding company, develops, manufactures, and sells non-patented pharmaceutical medicines in Mainland China and internationally. The company operates in two segments, Intermediates and Bulk Medicines, and Finished Drugs. It offers cephalosporin antibiotics cover intermediates, bulk medicines, and powder for injections; and specific medicines covering therapeutic areas for anti-HBV, anti-allergic, cardiovascular system, digestive system, urinary system, and endocrine system with dosage forms of tablets, capsules, and granules. The company was founded in 1995 and is headquartered in Wanchai, Hong Kong. Dawnrays Pharmaceutical (Holdings) Limited is a subsidiary of Fortune United Group Limited.

950 Employees
Last Reported Date: 04/10/15
Founded in 1995

dawnrays pharmaceutical hold (2348) Top Compensated Officers

Co-Founder, Chairman, Chief Executive Officer...
Total Annual Compensation: CNY867.0K
Co-Founder and Executive Director
Total Annual Compensation: CNY534.0K
Executive Director
Total Annual Compensation: CNY534.0K
Compensation as of Fiscal Year 2014.

dawnrays pharmaceutical hold (2348) Key Developments

Dawnrays Pharmaceutical (Holdings) Limited Provides Earnings Guidance for the Six Months Ended June 30, 2015

Dawnrays Pharmaceutical (Holdings) Limited provided earnings guidance for the six months ended June 30, 2015. For the six months, the company announced that based on the information currently available to the company and the preliminary assessment by the company's management with reference to the unaudited management accounts of the company and its subsidiaries for the five months ended 31 May 2015, the group expects approximately 50% year-on-year increase in its unaudited profit attributable to owners of the parent for the six months ended 30 June 2015. The increase in the group's Profit in the first half of 2015 was primarily attributable to the increase in revenue of high-gross-profit-margin system specific medicines compared with the corresponding period of 2014, as the Group's continued efforts towards the enhancement in the group's management control and the sales management as described in the company's 2014 annual report.

Dawnrays Pharmaceutical Holdings Ltd. Appoints EDE, Ronald Hao Xi as Non-Executive Director, Effective from June 15, 2015

The board of directors of Dawnrays Pharmaceutical (Holdings) Limited announced that Mr. EDE, Ronald Hao Xi has been appointed as a non-executive director of the Company, such appointment to take effect from 15 June 2015. Mr. EDE, Ronald Hao Xi has extensive experience in financial and business management in multinational companies. He currently holds the position of chief financial officer and company secretary of Biosensors International Group Ltd. He is also an independent director and a member of the audit committee and transactions committee of Mindray Medical International Ltd.

Dawnrays Pharmaceutical Holdings Ltd. Presents at Credit Suisse Asia Healthcare C-Level Conference, May-21-2015

Dawnrays Pharmaceutical Holdings Ltd. Presents at Credit Suisse Asia Healthcare C-Level Conference, May-21-2015 . Venue: Credit Suisse Office, Level 88, International Commerce Center, 1 Austin Road West, Kowloon, Hong Kong.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
2348:HK $7.51 HKD +0.09

2348 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for 2348.
View Industry Companies
 

Industry Analysis

2348

Industry Average

Valuation 2348 Industry Range
Price/Earnings 23.4x
Price/Sales 6.1x
Price/Book 3.8x
Price/Cash Flow 23.3x
TEV/Sales 5.3x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact DAWNRAYS PHARMACEUTICAL HOLD, please visit www.dawnrays.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.